(Q39424040)

11 September 2017

title

Effect of zanamivir on duration and resolution of influenza symptoms (English)

1 reference

11 September 2017

1 reference

Monto AS

1

1 reference

11 September 2017

Moult AB

series ordinal

2

1 reference

11 September 2017

Sharp SJ

series ordinal

3

1 reference

11 September 2017

publication date

1 November 2000

1 reference

11 September 2017

published in

Clinical Therapeutics

1 reference

11 September 2017

volume

22

1 reference

11 September 2017

issue

11

1 reference

11 September 2017

page(s)

1294-1305

1 reference

Influenza: quantifying morbidity and mortality

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983026-X

7 January 2021

Efficacy of influenza vaccine in nursing homes. Reduction in illness and complications during an influenza A (H3N2) epidemic

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983026-X

7 January 2021

Implications of viral resistance to amantadine in control of influenza A

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983026-X

7 January 2021

Emergence and apparent transmission of rimantadine-resistant influenza A virus in families

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983026-X

7 January 2021

Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983026-X

7 January 2021

A novel approach to antiviral therapy for influenza

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983026-X

7 January 2021

Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983026-X

7 January 2021

Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983026-X

7 January 2021

Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983026-X

7 January 2021

Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983026-X

7 January 2021

Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983026-X

7 January 2021

Zanamivir: a review of clinical safety

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983026-X

7 January 2021

Clinical signs and symptoms predicting influenza infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2983026-X

7 January 2021

10.1016/S0149-2918(00)83026-X

Identifiers

DOI

1 reference

11 September 2017

1 reference